UA130707C2 - Інгібітори line-1 для лікування захворювань цнс та системних захворювань - Google Patents
Інгібітори line-1 для лікування захворювань цнс та системних захворюваньInfo
- Publication number
- UA130707C2 UA130707C2 UAA202304574A UAA202304574A UA130707C2 UA 130707 C2 UA130707 C2 UA 130707C2 UA A202304574 A UAA202304574 A UA A202304574A UA A202304574 A UAA202304574 A UA A202304574A UA 130707 C2 UA130707 C2 UA 130707C2
- Authority
- UA
- Ukraine
- Prior art keywords
- inhibitor
- gime
- subject
- disease
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163161050P | 2021-03-15 | 2021-03-15 | |
| PCT/US2022/020362 WO2022197689A1 (en) | 2021-03-15 | 2022-03-15 | Line-1 inhibitors to treat cns and systemic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA130707C2 true UA130707C2 (uk) | 2026-04-22 |
Family
ID=83321069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202304574A UA130707C2 (uk) | 2021-03-15 | 2022-03-15 | Інгібітори line-1 для лікування захворювань цнс та системних захворювань |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240173346A1 (https=) |
| EP (1) | EP4308237A4 (https=) |
| JP (1) | JP2024511973A (https=) |
| KR (1) | KR20230157430A (https=) |
| CN (1) | CN117355312A (https=) |
| AU (1) | AU2022237405A1 (https=) |
| BR (1) | BR112023018714A2 (https=) |
| CA (1) | CA3211369A1 (https=) |
| CL (1) | CL2023002746A1 (https=) |
| DO (1) | DOP2023000192A (https=) |
| IL (1) | IL305869A (https=) |
| MA (1) | MA62910A1 (https=) |
| MX (1) | MX2023010657A (https=) |
| UA (1) | UA130707C2 (https=) |
| WO (1) | WO2022197689A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12350264B2 (en) | 2019-11-22 | 2025-07-08 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder |
| WO2021102423A1 (en) | 2019-11-22 | 2021-05-27 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| US20250170158A1 (en) * | 2022-02-22 | 2025-05-29 | Rome Therapeutics, Inc. | Methods of treating medical conditions using censavudine or a related compound |
| IL315480A (en) | 2022-03-15 | 2024-11-01 | Rome Therapeutics Inc | Compounds and methods for treating disease |
| WO2023178128A1 (en) * | 2022-03-15 | 2023-09-21 | Rome Therapeutics, Inc. | Methods of treating medical conditions using islatravir or a related compound |
| CA3246792A1 (en) * | 2022-03-30 | 2023-10-05 | Transposon Therapeutics, Inc. | NUCLEOSIDE LINE-1 INHIBITORS |
| WO2024129788A1 (en) * | 2022-12-13 | 2024-06-20 | Brown University | Small molecule inhibitors of the line-1 endonuclease domain |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2535045T3 (es) * | 2003-04-10 | 2015-05-04 | Vanderbilt Royalty Sub L.P. | Usos y composiciones para administración de capsaicina |
| EP2965760A1 (en) * | 2014-07-09 | 2016-01-13 | Université de Montpellier | Combination of antiretroviral agents for use in the prevention or treatment of chronic inflammatory diseases |
| CN105012305A (zh) * | 2015-07-24 | 2015-11-04 | 福建广生堂药业股份有限公司 | 拉米夫定及其药用盐治疗老年性黄斑部病变的用途 |
| RU2726210C2 (ru) * | 2018-12-27 | 2020-07-09 | Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" | Комбинация противовирусных средств, набор и способ лечения на ее основе |
| EP3914604B1 (en) * | 2019-01-25 | 2026-03-04 | Brown University | Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders |
| TW202104210A (zh) * | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
-
2022
- 2022-03-15 KR KR1020237034983A patent/KR20230157430A/ko active Pending
- 2022-03-15 JP JP2023556734A patent/JP2024511973A/ja active Pending
- 2022-03-15 IL IL305869A patent/IL305869A/en unknown
- 2022-03-15 AU AU2022237405A patent/AU2022237405A1/en active Pending
- 2022-03-15 BR BR112023018714A patent/BR112023018714A2/pt unknown
- 2022-03-15 CN CN202280034771.5A patent/CN117355312A/zh active Pending
- 2022-03-15 MX MX2023010657A patent/MX2023010657A/es unknown
- 2022-03-15 US US18/550,498 patent/US20240173346A1/en active Pending
- 2022-03-15 WO PCT/US2022/020362 patent/WO2022197689A1/en not_active Ceased
- 2022-03-15 EP EP22772048.9A patent/EP4308237A4/en active Pending
- 2022-03-15 CA CA3211369A patent/CA3211369A1/en active Pending
- 2022-03-15 UA UAA202304574A patent/UA130707C2/uk unknown
- 2022-03-15 MA MA62910A patent/MA62910A1/fr unknown
-
2023
- 2023-09-14 CL CL2023002746A patent/CL2023002746A1/es unknown
- 2023-09-14 DO DO2023000192A patent/DOP2023000192A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022237405A1 (en) | 2023-11-02 |
| WO2022197689A1 (en) | 2022-09-22 |
| KR20230157430A (ko) | 2023-11-16 |
| MA62910A1 (fr) | 2023-12-29 |
| EP4308237A1 (en) | 2024-01-24 |
| DOP2023000192A (es) | 2024-02-29 |
| CL2023002746A1 (es) | 2024-04-05 |
| EP4308237A4 (en) | 2025-03-05 |
| US20240173346A1 (en) | 2024-05-30 |
| CN117355312A (zh) | 2024-01-05 |
| MX2023010657A (es) | 2023-09-21 |
| BR112023018714A2 (pt) | 2023-10-24 |
| IL305869A (en) | 2023-11-01 |
| CA3211369A1 (en) | 2022-09-22 |
| JP2024511973A (ja) | 2024-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA130707C2 (uk) | Інгібітори line-1 для лікування захворювань цнс та системних захворювань | |
| US20250017939A1 (en) | Antiviral Therapy | |
| KR20240017910A (ko) | 인지 향상제로서 line-1 억제제 | |
| WO2014201426A2 (en) | Triazol-1-ol analogs anti-retroviral latency drugs | |
| EP1113802B1 (en) | Antiviral combinations of lamivudine and adefovir | |
| JP2002534390A (ja) | 癌治療におけるアデノシンアゴニスト類の使用 | |
| US20220016118A1 (en) | Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof | |
| OA21831A (en) | LINE-1 inhibitors to treat CNS and systemic diseases. | |
| US10821101B2 (en) | Pharmaceutical composition for preventing or treating AIDS comprising rhodanine derivative | |
| AU2017268621B2 (en) | Antiviral therapy | |
| KR20010075202A (ko) | 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제 | |
| CN117883450A (zh) | 一种预防或治疗弥漫性大b细胞淋巴瘤的联合用药物组合物及其应用 | |
| US20150104416A1 (en) | Leukemic Stem Cell Ablation | |
| WO2025183089A1 (ja) | 潜伏感染しているｈｉｖを再活性化するための組成物 | |
| AU2014202404C1 (en) | Antiviral therapy | |
| TW202023570A (zh) | 用於治療癌症的自然殺手細胞與環磷醯胺的組合 | |
| KR20070114806A (ko) | 바이러스 감염 치료에의 티오포스포노포름산 및 ｎｒｔｉ의용도 | |
| HK40003467B (en) | Combinations of dolutegravir and lamivudine for the treatment of hiv infection |